Cargando…

Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites

INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled st...

Descripción completa

Detalles Bibliográficos
Autores principales: Bogacz-Piaseczyńska, Agnieszka, Bożek, Andrzej, Pastuszczak, Maciej, Zalejska-Fiolka, Jolanta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485758/
https://www.ncbi.nlm.nih.gov/pubmed/37692262
http://dx.doi.org/10.5114/ada.2023.129456
_version_ 1785102858095427584
author Bogacz-Piaseczyńska, Agnieszka
Bożek, Andrzej
Pastuszczak, Maciej
Zalejska-Fiolka, Jolanta
author_facet Bogacz-Piaseczyńska, Agnieszka
Bożek, Andrzej
Pastuszczak, Maciej
Zalejska-Fiolka, Jolanta
author_sort Bogacz-Piaseczyńska, Agnieszka
collection PubMed
description INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months’ AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed. RESULTS: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. CONCLUSIONS: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT.
format Online
Article
Text
id pubmed-10485758
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-104857582023-09-09 Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites Bogacz-Piaseczyńska, Agnieszka Bożek, Andrzej Pastuszczak, Maciej Zalejska-Fiolka, Jolanta Postepy Dermatol Alergol Original Paper INTRODUCTION: Allergen immunotherapy (AIT) has no clear recommendation for atopic dermatitis (AD). AIM: To evaluate the effect of AIT on house dust mites (HDM) in AD patients sensitised to HDM with different baseline molecular profiles of antigens. MATERIAL AND METHODS: In this placebo-controlled study, 61 patients with moderate-to-severe AD allergy symptoms and HDM allergy were included. They received a 12 months’ AIT with the use of HDM allergen extract or placebo. The authors adopted their AD improvement criterion after 1 year of AIT as a reduction of all examined indicators by at least 50% from the baseline for %BSA, TMS, and EASI scores. Additionally, the influence of individual HDM molecules on the final AIT effect was analysed. RESULTS: Finally, from the 24 desensitised patients, 15 achieved a positive expected effect after 12 months of HDM AIT. None of the patients who received a placebo had an improvement in AD of at least 50% after 1 year of follow-up. Patients with polysensitisation less frequently achieved the expected HDM AIT effect than patients monosensitised to mites (p < 0.05). The presence of sensitisation to rDer p 1 (odds ratio = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT effect. The presence of sensitisation to rDer p 1 (OR = 4.35, 95% CI: 4.01–4.56) and/or rDer p 2 (OR = 2.16, 95% CI: 1.98–2.33) and/or rDer f 2 (OR = 1.41, 95% CI: 1.55–1.78) molecules significantly increased the efficacy of AIT. CONCLUSIONS: HDM AIT could be helpful for patients with moderate-to-severe AD and sensitised to HDM as an add-on therapy. Various HDM molecules may affect the effectiveness of the expected AIT. Termedia Publishing House 2023-07-14 2023-08 /pmc/articles/PMC10485758/ /pubmed/37692262 http://dx.doi.org/10.5114/ada.2023.129456 Text en Copyright: © 2023 Termedia Sp. z o. o. https://creativecommons.org/licenses/by-nc-sa/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Original Paper
Bogacz-Piaseczyńska, Agnieszka
Bożek, Andrzej
Pastuszczak, Maciej
Zalejska-Fiolka, Jolanta
Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title_full Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title_fullStr Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title_full_unstemmed Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title_short Molecular profiling of allergen-antibody IgE might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
title_sort molecular profiling of allergen-antibody ige might decide about the efficacy of allergen immunotherapy in a patient with atopic dermatitis and allergy to house dust mites
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485758/
https://www.ncbi.nlm.nih.gov/pubmed/37692262
http://dx.doi.org/10.5114/ada.2023.129456
work_keys_str_mv AT bogaczpiaseczynskaagnieszka molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites
AT bozekandrzej molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites
AT pastuszczakmaciej molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites
AT zalejskafiolkajolanta molecularprofilingofallergenantibodyigemightdecideabouttheefficacyofallergenimmunotherapyinapatientwithatopicdermatitisandallergytohousedustmites